SCHEMBL20522391

SCHEMBL20522391

Nc1cccc(F)c1-c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.46
ALDH1A1 P00352 3/20 0.46
CYP1A2 P05177 3/20 0.46
CYP2C19 P33261 3/20 0.46
CYP2C9 P11712 2/20 0.46
TTR P02766 1/20 0.42
HPGD P15428 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
ATM Q13315 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30610420 1.00 CYP3A4 (0.46) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL30234670 0.89 CYP3A4 (0.43) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL3784827 0.87 TAAR1 (0.45) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL3793176 0.84 CYP3A4 (0.45) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL13615034 0.84 TTR (0.56) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL4910768 0.83 ADORA2A (0.41) CYP3A4CYP1A2CYP2C19TTRL3MBTL1
SCHEMBL20522406 0.83 CYP1A2 (0.49) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL9681067 0.81 CD44 (0.46) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL2934681 0.79 TSHR (0.43) CYP3A4ALDH1A1CYP1A2CYP2C19CYP2C9
SCHEMBL2498725 0.79 ALOX5AP (0.44) CYP3A4CYP1A2CYP2C19CYP2C9TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001873-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2026-01-01 US disclosed
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001873-A1 NOVEL INHIBITORS GLS, GLS2, SULT1E1 CYP3A4 632/4885ALDH1A1 1183/4885CYP1A2 839/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT CYP3A4 987/4885ALDH1A1 1681/4885CYP1A2 723/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS CYP3A4 1145/4885ALDH1A1 1490/4885CYP1A2 714/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 CYP3A4 1109/4885ALDH1A1 1415/4885CYP1A2 744/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT CYP3A4 953/4885ALDH1A1 1184/4885CYP1A2 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.